leisure time -WSS

leisure time

author：knowledge 2025-09-27 11:32:36 - browse：58

When is negative data positive enough? Who gets credit for scientific breakthroughs? And wasn’t biotech supposed to bounce back?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain the story of Svetlana Mojsov, a chemist who played a vital role in the discovery of GLP-1 who has spent decades fighting for proper recognition. We also discuss the latest news in the life sciences, including the FDA hearing on a BrainStorm Cell Therapeutics’ polarizing ALS treatment, the end of the road for a once-vaunted drug developer, and the sorry state of biotech stocks.

For more on what we cover, here’s the Mojsov story; here’s the latest on BrainStorm; here’s the news on Intercept Pharmaceuticals; here’s more on the biotech market; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Merck to buy EyeBio, maker of eye drug, as it grows pipeline

WSS

Scientists successfully use ultrasound imaging to map brain activity

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Heat waves linked to early deliveries, preterm births in new study

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Lab trade group sues FDA to halt regulation of lab

Heat waves linked to early deliveries, preterm births in new study

knowledge

leisure time

Wikipedia

Sports medicine is finally prioritizing gender equality

Heat waves linked to early deliveries, preterm births in new study

After affirmative action ruling, medical educators look to 'holistic review'

Do more moles mean more problems? Not so, says new study

Moonlake's readout produced a cash windfall. Risks remain

The drug industry sees a key ally in the Senate prevail

The cancer drug shortage isn’t new — and neither are the solutions

Dramatically reducing cancer deaths requires the PASTEUR Act

Virginia high school admissions case could be legal follow

Childbirth

hotspot

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Report: NIH

iTeos Therapeutics debuts first data on TIGIT

Influencer to be charged after chaos erupts in New York City's Union Square

What Mike Pence has said that could be used in a Donald Trump trial

explore

focus

entertainment

leisure time